Rofecoxib Articles
Report claims DTC ads fuel drug litigation
10 July 2006
Osteoporosis - the
26 June 2006
Japan stock market week to June 12, 2006
19 June 2006
US FDA approves Merck & Co's Gardasil: First cervical cancer vacc, potential blockbuster
19 June 2006
New drugs will drive Rx pain therapy market
5 June 2006
Merck & Co corrects APPROVe trial analysis
5 June 2006
US seniors call for ban on DTC ads
5 June 2006
Gardasil gets FDA nod for cervical cancer
29 May 2006
APPROVe study: Vioxx users not at more CV risk
22 May 2006
Merck & Co loses another Vioxx case
1 May 2006
Stock Commentary - New York - week to April 10, 2006
17 April 2006
Split jury verdict on Merck & Co's Vioxx
10 April 2006
FDA Commissioner nomination looms
20 March 2006
Stock Commentary - New York week to Feb 20, 2006
27 February 2006
Bark extract reduces osteoarthritic pain
27 February 2006
Merck & Co wins federal Vioxx case
27 February 2006
FDA Safety Board comes under fire
27 February 2006
AEI blames FDA for pipeline slowdown
20 February 2006
Merck & Co beats forecasts; profit up 2%
6 February 2006
FDA should be given more power
30 January 2006
Stock Commentary - New York week to Dec 12
19 December 2005
Disappointment for Merck & Co as Judge rules Vioxx case a mistrial
19 December 2005
Editor's views on SkyePharma sale; Merck & Co's situation
5 December 2005
Vioxx legal aid refusal: end of UK Rx litigation?
5 December 2005
Cider Sante sold to Pharmexx for 8M euros
5 December 2005
Report sees "fundamental flaws" in many Rx studies; urges
5 December 2005
First class action on Vioxx in Australia
19 September 2005
Stock Commentary - Europe - week to Sept 5
12 September 2005
Stock Commentary - New York week to Aug 15
5 September 2005
Stock Commentary - Europe - week to Aug 15
5 September 2005
Australian pharma warns over patent losses
22 August 2005
Stock Commentary - New York
1 August 2005
Tax charges slice Merck & Co's 2nd-qtr income
1 August 2005
US FDA calls for ED drug vision warning
18 July 2005
Glimmer of hope for Merck & Co's Vioxx
18 July 2005
Merck & Co fails to delay first Vioxx trial
11 July 2005
Stock Commentary - New York
4 July 2005
Stock Commentary - New York
20 June 2005
Australis's TGA seeks greater powers
6 June 2005
Stock Commentary - New York
30 May 2005
Stock Commentary - New York
16 May 2005
New CEO for Merck & Co, as Gilmartin quits
16 May 2005
Merck & Co calls for dismissal of law suit
27 April 2005
US $4.5B DTC industry faces uncertain future
27 April 2005
Vioxx loss drags on Merck & Co results
22 April 2005
Three Bextra law suits filed against Pfizer
18 April 2005
FDA clears Merck & Co's enhanced Fosamax
18 April 2005
US FDA "heads-up" on new Rx ad guidelines
14 March 2005
Americans understand Rx risk/benefits: study
14 March 2005
Provalis half-year 2004 results in line
7 March 2005
Evidence for CV risks of COX-2s; NEJM report
28 February 2005
Stock Commentary - New York
28 February 2005
Editor's views on COX-2 reviews; recent M&A activity
28 February 2005
Bayer says FDA committee supports Aleve safety
28 February 2005
US FDA panel says COX-2s can be sold, OKs Vioxx' return to market?
28 February 2005
Merck & Co updates on Vioxx litigation
28 February 2005
Stock Commentary - New York
21 February 2005
Panel endorses use of Gruenenthal's Zydol
21 February 2005
US FDA sets up Drug Safety Oversight Board, will inform public about emerging concerns
21 February 2005
Stock Commentary - New York
14 February 2005
Novartis considers limited initial approval of Prexige in the USA
14 February 2005
Merck & Co says "no bankruptcy" and "no major merger"
14 February 2005
Merck & Co starts Ph II trial of HIV vaccine
31 January 2005
Vioxx could be cause of 140,000 heart attacks in the USA
31 January 2005
Slowdown in revenue growth forecast for AstraZeneca
31 January 2005
- US Supreme Court says patent settlement can "sometimes" be illegal
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Daiichi Sankyo files for Japanese approval of Prasugrel
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
